{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:07:18Z","timestamp":1787508438360,"version":"build-2736575974"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) regimen has been established as a systemic chemotherapy for patients with urothelial carcinoma. However, it is rarely used in Japan owing to the challenges associated with managing the related adverse events. This study aimed to optimize the dd-MVAC protocol for Japanese patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Criteria were developed to adjust the doses of anticancer drugs used in dd-MVAC. In this regimen, the initial cycle of methotrexate and cisplatin was administered at 75% of the full dose. Patients who did not experience significant toxicities during the first cycle subsequently received the full dose starting from the second cycle. Additionally, the doses of methotrexate and cisplatin were adjusted according to the Cockcroft-Gault creatinine clearance. Based on these criteria, patients with urothelial carcinoma underwent dd-MVAC between August 2018 and May 2023, and all patients were scheduled to undergo six cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 86 patients received dd-MVAC, with 36, 15, and 35 patients receiving it as neoadjuvant, adjuvant, and salvage chemotherapy, respectively. Fifty-nine patients (68.6%) completed the six scheduled cycles. Grade\u00a0\u2265\u00a03 toxicities of Common Terminology Criteria for Adverse Events were observed in 76 (88.4%) patients; however, most were manageable. In the neoadjuvant cohort, the pathological complete response rate was 52.2% among patients with clinical N0 lower tract urothelial carcinoma. High levels of alkaline phosphatase at the initiation of treatment were correlated with failure to complete six cycles of dd-MVAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adjusting the dd-MVAC regimen based on renal function and significant adverse events may result in a high completion rate of scheduled treatments in Japanese patients with urothelial carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf001","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T07:17:04Z","timestamp":1735888624000},"page":"421-427","source":"Crossref","is-referenced-by-count":8,"title":["Optimization of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy for Japanese patients with urothelial carcinoma"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-2874","authenticated-orcid":false,"given":"Taketo","family":"Kawai","sequence":"first","affiliation":[{"name":"Department of Urology, International University of Health and Welfare Ichikawa Hospital , 6-1-14 Konodai, Ichikawa, Chiba 272-0827 ,","place":["Japan"]},{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]},{"name":"Department of Urology, Teikyo University School of Medicine , 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-4294","authenticated-orcid":false,"given":"Satoru","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Ambe","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Saegusa","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimpei","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]},{"name":"Department of Urology, Kyorin University School of Medicine , 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuumi","family":"Tokura","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University School of Medicine , 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazuki","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University School of Medicine , 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Nara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University School of Medicine , 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kamei","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Kakutani","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Niimi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University School of Medicine , 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine , The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"2025040711073831300_ref1","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","article-title":"European Organization for Research and Treatment of cancer genitourinary tract cancer cooperative group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of cancer protocol no. 30924","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025040711073831300_ref2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"EORTC Genito-urinary cancer group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"2025040711073831300_ref3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","article-title":"VESPER trial investigators. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: Chemotherapy toxicity and pathological responses","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"2025040711073831300_ref4","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"VESPER trial investigators. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025040711073831300_ref5","doi-asserted-by":"publisher","volume-title":"Muscle-invasive and metastatic bladder cancer","author":"EAU Guidelines","DOI":"10.1016\/j.euo.2024.05.010"},{"key":"2025040711073831300_ref6","volume-title":"National comprehensive cancer network, 3025 chemical road, suite 100, Plymouth meeting, PA 19462","author":"NCCN Clinical Practice Guidelines in Oncology","year":"2024"},{"key":"2025040711073831300_ref7","first-page":"213","article-title":"Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder","volume":"53","author":"Maeda","year":"2007","journal-title":"Hinyokika Kiyo"},{"key":"2025040711073831300_ref8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/jjco\/28.8.497","article-title":"Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: A prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese urothelial cancer research group","volume":"28","author":"Kuroda","year":"1998","journal-title":"Jpn J Clin Oncol"},{"key":"2025040711073831300_ref9","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/iju.15014","article-title":"Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020)","volume":"29","author":"Taguchi","year":"2022","journal-title":"Int J Urol"},{"key":"2025040711073831300_ref10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/iju.15411","article-title":"Japan urological oncology group. Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan","volume":"31","author":"Kita","year":"2024","journal-title":"Int J Urol"},{"key":"2025040711073831300_ref11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0305-7372(95)90010-1","article-title":"Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function","volume":"21","author":"Kintzel","year":"1995","journal-title":"Cancer Treat Rev"},{"key":"2025040711073831300_ref12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"2025040711073831300_ref13","first-page":"1","volume-title":"Onco-nephrology curriculum. Chap. 12","author":"Latcha","year":"2016"},{"key":"2025040711073831300_ref14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10157-017-1448-z","article-title":"Guidelines for treatment of renal injury during cancer chemotherapy 2016","volume":"22","author":"Horie","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2025040711073831300_ref15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/bco2.81","article-title":"Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma","volume":"2","author":"Murakami","year":"2021","journal-title":"BJUI Compass"},{"key":"2025040711073831300_ref16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12894-022-01139-9","article-title":"Comparison of full-dose gemcitabine\/cisplatin, dose-reduced gemcitabine\/cisplatin, and gemcitabine\/carboplatin in real-world patients with advanced urothelial carcinoma","volume":"22","author":"Sugimoto","year":"2022","journal-title":"BMC Urol"},{"key":"2025040711073831300_ref17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2013.52.4785","article-title":"Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates","volume":"32","author":"Choueiri","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025040711073831300_ref18","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.21037\/tcr-23-1190","article-title":"Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors?","volume":"12","author":"Jiang","year":"2023","journal-title":"Transl Cancer Res"},{"key":"2025040711073831300_ref19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.5551\/jat.63646","article-title":"Elevated levels of serum alkaline phosphatase are associated with increased risk of cardiovascular disease: A prospective cohort study","volume":"30","author":"Liu","year":"2023","journal-title":"J Atheroscler Thromb"},{"key":"2025040711073831300_ref20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00345-015-1636-y","article-title":"Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: Efficacy and safety compared with classic MVAC and gemcitabine\/cisplatin","volume":"34","author":"Putte","year":"2016","journal-title":"World J Urol"},{"key":"2025040711073831300_ref21","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","article-title":"Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer","volume":"4","author":"Peyton","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025040711073831300_ref22","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.juro.2017.12.062","article-title":"Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy","volume":"199","author":"Zargar","year":"2018","journal-title":"J Urol"},{"key":"2025040711073831300_ref23","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1016\/j.clgc.2020.02.010","article-title":"Downstaging of muscle-invasive bladder cancer using neoadjuvant gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as single regimens or as switch therapy modalities","volume":"18","author":"Ruplin","year":"2020","journal-title":"Clin Genitourin Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/4\/421\/61439694\/hyaf001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/4\/421\/61439694\/hyaf001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:05:26Z","timestamp":1744023926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/4\/421\/7954233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf001","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,15]]}}}